WO2009115429A1 - Préparation alimentaire et composition pharmaceutique contenant un extrait embryonnaire - Google Patents
Préparation alimentaire et composition pharmaceutique contenant un extrait embryonnaire Download PDFInfo
- Publication number
- WO2009115429A1 WO2009115429A1 PCT/EP2009/052764 EP2009052764W WO2009115429A1 WO 2009115429 A1 WO2009115429 A1 WO 2009115429A1 EP 2009052764 W EP2009052764 W EP 2009052764W WO 2009115429 A1 WO2009115429 A1 WO 2009115429A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- embryonic
- egg
- preparation according
- pharmaceutical composition
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000000284 extract Substances 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 210000001647 gastrula Anatomy 0.000 claims abstract description 7
- 201000004384 Alopecia Diseases 0.000 claims abstract description 6
- 230000013020 embryo development Effects 0.000 claims abstract description 6
- 230000003676 hair loss Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 208000024963 hair loss Diseases 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 239000013543 active substance Substances 0.000 claims abstract description 3
- 230000001796 anti-degenerative effect Effects 0.000 claims abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 claims abstract 4
- 241000282472 Canis lupus familiaris Species 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 210000002969 egg yolk Anatomy 0.000 claims description 6
- 241000282326 Felis catus Species 0.000 claims description 5
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 230000036620 skin dryness Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000016255 tiredness Diseases 0.000 description 5
- 230000003867 tiredness Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940111782 egg extract Drugs 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 210000002023 somite Anatomy 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/08—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from eggs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L15/00—Egg products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- the applicant has been able to verify that the administration of embryo extracts taken in a stage before the extraction stages used up until now, and very specific of embryonic development, has surprisingly revitalizing effects that are0 most likely related to a significant effect on the cell division rate.
- the embryonic germ must be obtained before the formation of segmented mesodermal tissue masses, or somites, in the embryonic development, but once the blastula phase has been completed.
- the embryonic germ is obtained in the food preparation of the invention when the three embryonic ectoblast-mesoblast-entoblast layers have been developed in a fertilized and incubated egg for a specific period, whereby the food preparation comprises at least one embryonic germ in the final gastrula phase.
- the embryonic germ is extracted from a hen egg during the period comprised between 18 and 30 hours after its incubation.
- the preparation further comprises part of the yolk of the egg sucked during the extraction of the germ by suction.
- the preparation is preferably frozen for its conservation and subsequent oral administration.
- the administration of the preparation in humans is indicated as a regenerating agent in the event of skin dryness or hair loss.
- the administration of the preparation in animals is indicated as a revitalizing agent and stimulant of the defences in the event of suffering from infectious or parasitic diseases such as Leishmaniasis in dogs or viral immunodeficiencies in cats.
- a pharmaceutical composition containing as an active substance at least one embryonic extract in the final gastrula embryonic development stage extracted from a fertilized and incubated egg is disclosed.
- composition is intended for its use in antidegenerative treatments, for treating arthrosis, cirrhosis, nephritis or neurodegenerative processes.
- composition is also intended for its use in regenerative treatments in mammals.
- composition is intended for its use as a coadjuvant of treatments against cancer, such as radiotherapy and chemotherapy.
- a fertilized hen egg is removed from an incubator after a period comprised between 18 and 36 hours after its incubation.
- An embryonic germ in the final gastrula phase, before the formation of somites, is thus achieved.
- the content obtained after the breaking of the shell, formed by the yolk and the white, is subsequently deposited on a sterile tray.
- the yolk is shaken by rocking the tray until the embryonic germ is located in a dorsal and centred position.
- the suction of said embryonic germ is then carried out, which germ is contained together with the surrounding yolk in an amount of volume approximately between 0.5 and 2 ml, according to the suction carried out.
- a sterile syringe, plunger or pipette is used for the mentioned suction, in a way which is known in itself.
- a treatment based on the preparation according to the invention was started.
- a dose of 2 ml was administered three times a day, follicle growth, normalization of prostatic symptoms, normalization of the cardiac rhythm and the blood pressure starting to be observed six months after the start of the treatment. After 5 years it can be verified that the quality of life of said patient has been improved.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
L'invention porte sur une préparation alimentaire et sur une composition pharmaceutique contenant un extrait embryonnaire et sur leurs utilisations respectives. La préparation alimentaire comprend un germe embryonnaire dans la phase gastrula finale extrait d'un œuf fertilisé et incubé. De plus, la composition pharmaceutique contient en tant que substance active un extrait embryonnaire dans le stade de développement embryonnaire de gastrula finale extrait d'un œuf fertilisé et incubé. Ladite préparation est utilisée en tant que complément alimentaire pour la prévention de la chute des cheveux. De plus, ladite composition pharmaceutique peut être utilisée en tant que médicament pour des traitements antidégénératifs.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200800802A ES2337537B8 (es) | 2008-03-19 | 2008-03-19 | Preparado alimenticio y composicion farmaceutica que contiene un extracto embrionario y sus respectivos usos. |
| ESP200800802 | 2008-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009115429A1 true WO2009115429A1 (fr) | 2009-09-24 |
Family
ID=40833510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2009/052764 WO2009115429A1 (fr) | 2008-03-19 | 2009-03-10 | Préparation alimentaire et composition pharmaceutique contenant un extrait embryonnaire |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2337537B8 (fr) |
| WO (1) | WO2009115429A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013053503A1 (fr) | 2011-10-13 | 2013-04-18 | Cunill Aixela Juan | Préparation à base d'œufs à propriétés régénérantes, analgésiques et/ou anti-inflammatoires |
| ITMI20120008A1 (it) * | 2012-01-04 | 2013-07-05 | Biava Maura | Composizioni ad attività anti-neurodegenerativa |
| WO2018134460A1 (fr) * | 2017-01-19 | 2018-07-26 | Liofilizados Girona, Sl | Préparation à base d'oeuf à propriétés anti-inflammatoires et antioxydantes |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4400640A1 (de) * | 1994-01-12 | 1995-07-13 | Eftag Entstaubung Foerdertech | Verwendung von, Mittel mit und Verfahren zur Herstellung eines Arzneimittels mit Embryonalgewebe |
| WO1998011905A1 (fr) * | 1996-09-20 | 1998-03-26 | Adriana Carluccio | Composition pharmaceutique contenant un extrait embryonnaire ou d'uterus gravide, utilise comme substance active et procede de preparation de ladite composition |
| CA2197050A1 (fr) * | 1997-02-07 | 1998-08-07 | Morton P. Shulman | Agents anticancereux issus d'oeufs en coquille fecondes incubes |
| FR2778850A1 (fr) * | 1998-05-22 | 1999-11-26 | Jacques Vincent Cavaille | Composition pharmaceutique ralentissant le vieillisement de l'organisme des mammiferes |
| EP1374703A1 (fr) * | 2002-06-20 | 2004-01-02 | Pier Mario Biava | Utilisation d'un extrait embryonnaire d'origine animale - non humaine - pour la préparation d'une substance nutritive et d'un complément alimentaire diététique-nutraceutique |
| US20070275036A1 (en) * | 2006-05-18 | 2007-11-29 | Celldyne Biopharma, Llc | Avian follistatin product |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888172A (en) * | 1982-09-23 | 1989-12-19 | Alfaceu Corporation | Pharmaceutical for treating tumors and methods for making it |
| ITMI20051572A1 (it) * | 2005-08-12 | 2007-02-13 | Alberto Astaldi | Composizione farmaceutica contenente come sostanza attiva una frazione proteica estratta da embrioni di ovipari nel periodo del differenziamento cellulare e relativo processo di preparazione |
-
2008
- 2008-03-19 ES ES200800802A patent/ES2337537B8/es not_active Expired - Fee Related
-
2009
- 2009-03-10 WO PCT/EP2009/052764 patent/WO2009115429A1/fr active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4400640A1 (de) * | 1994-01-12 | 1995-07-13 | Eftag Entstaubung Foerdertech | Verwendung von, Mittel mit und Verfahren zur Herstellung eines Arzneimittels mit Embryonalgewebe |
| WO1998011905A1 (fr) * | 1996-09-20 | 1998-03-26 | Adriana Carluccio | Composition pharmaceutique contenant un extrait embryonnaire ou d'uterus gravide, utilise comme substance active et procede de preparation de ladite composition |
| CA2197050A1 (fr) * | 1997-02-07 | 1998-08-07 | Morton P. Shulman | Agents anticancereux issus d'oeufs en coquille fecondes incubes |
| FR2778850A1 (fr) * | 1998-05-22 | 1999-11-26 | Jacques Vincent Cavaille | Composition pharmaceutique ralentissant le vieillisement de l'organisme des mammiferes |
| EP1374703A1 (fr) * | 2002-06-20 | 2004-01-02 | Pier Mario Biava | Utilisation d'un extrait embryonnaire d'origine animale - non humaine - pour la préparation d'une substance nutritive et d'un complément alimentaire diététique-nutraceutique |
| US20070275036A1 (en) * | 2006-05-18 | 2007-11-29 | Celldyne Biopharma, Llc | Avian follistatin product |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013053503A1 (fr) | 2011-10-13 | 2013-04-18 | Cunill Aixela Juan | Préparation à base d'œufs à propriétés régénérantes, analgésiques et/ou anti-inflammatoires |
| JP2014530223A (ja) * | 2011-10-13 | 2014-11-17 | オヴィヴィティ グループ，エス． エル． | 再生性、鎮痛性および／または抗炎症性を有する卵調製物 |
| RU2585049C2 (ru) * | 2011-10-13 | 2016-05-27 | Овивити Груп, С.Л. | Препарат из яиц с регенерирующими, анальгезирующими и противовоспалительными свойствами |
| US9717764B2 (en) | 2011-10-13 | 2017-08-01 | Ovivity Group, S.L. | Egg preparation with regenerating, analgesic and/or anti-inflammatory properties |
| ITMI20120008A1 (it) * | 2012-01-04 | 2013-07-05 | Biava Maura | Composizioni ad attività anti-neurodegenerativa |
| WO2018134460A1 (fr) * | 2017-01-19 | 2018-07-26 | Liofilizados Girona, Sl | Préparation à base d'oeuf à propriétés anti-inflammatoires et antioxydantes |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2337537B8 (es) | 2011-08-01 |
| ES2337537B2 (es) | 2011-02-02 |
| ES2337537A1 (es) | 2010-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006792B (zh) | 一种防治畜禽肠道疾病的中兽药及其制备方法与饲料 | |
| US8613962B2 (en) | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent | |
| CN104606260B (zh) | 牛樟芝子实体萃取物用于改善化疗副作用的用途 | |
| JP6209579B2 (ja) | 補助化療薬品とされる医薬組成物その用途 | |
| WO2009115429A1 (fr) | Préparation alimentaire et composition pharmaceutique contenant un extrait embryonnaire | |
| CN110201142A (zh) | 一种用于防治鸡输卵管炎的复方制剂及其制备方法 | |
| RU2585049C2 (ru) | Препарат из яиц с регенерирующими, анальгезирующими и противовоспалительными свойствами | |
| KR20080009695A (ko) | 연골대사 이상질환 개선용 건강식품 및 의약품 조성물 | |
| RU2549496C1 (ru) | Гомеопатическое лекарственное средство, оказывающее стресспротективное и ростостимулирующее действие, регулирующее обмен веществ у молодняка сельскохозяйственных животных и птицы | |
| CN1826133A (zh) | 治疗经化疗的癌症患者的方法 | |
| CN113908149A (zh) | 刺芒柄花素在制备防治急性肺损伤药物中的用途 | |
| WO2005067948A2 (fr) | Medicament biologique pour le traitement de diverses maladies dues a differents virus, infection bacterienne | |
| CN101491518B (zh) | 一种用于治疗肿瘤的组合物 | |
| KR20020025433A (ko) | 동물의 기능강화 조성물 및 복합물질 | |
| CN104208683A (zh) | 一种抗鸭病毒性疾病的药物组合物、冻干粉、制备方法及应用 | |
| CN109620877A (zh) | 纯中药禽用抗细菌病制剂及其制备方法和使用方法 | |
| RU2077888C1 (ru) | Способ лечения лучевой болезни у животных | |
| Tripathi | Pharmaceutical from Animals | |
| RU2505298C1 (ru) | Способ лечения острых отравлений животных неоникотиноидными инсектицидами | |
| RU2572215C1 (ru) | Терапевтическое и энергетическое средство для животных | |
| JP2002145791A (ja) | 抗炎症性組成物 | |
| CN104367993A (zh) | 乳铁蛋白在疼痛治疗中的应用 | |
| Yandagiin et al. | Grasshoppers: row materials in traditional medicine | |
| KR20110124604A (ko) | 전복 내장 추출물을 유효성분으로 하는 항암 증진 또는 암 전이 억제용 조성물 | |
| KR20040067390A (ko) | 한약재를 이용한 소화기계통 및 혈관계통의 질환보조치료제의제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09722797 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09722797 Country of ref document: EP Kind code of ref document: A1 |